The independent bid committee of Vigmed continues to recommend the shareholders of Vigmed to accept the offer by Greiner Bio-One
Yesterday on 21 March 2017, the independent bid committee (the “Bid committee”)
, appointed by the Board of Directors of Vigmed Holding AB (“Vigmed”) following the public offer by Greiner Bio-One GmbH on 27 February 2017 (the “Offer”), was informed of an announcement made by Beijing Topraise Medical Technology (
). The Bid Committee has not received any other information pertaining to the potential loan offer than set out in the announcement. The information in the announcement does not provide any reason for the Bid Committee to revise its position on the Bid and, accordingly, the Bid Committee continues to recommend the shareholders of Vigmed to accept the Offer.
 The Bid Committee consists of the Board members Sten Dahlborg (chairman), Thomas Baier and Axel Sjöblad, who do not have any conflicts of interest in relation to GBO or the Offer.
For further information contact:
Chairman of the Board Sten Dahlborg, +46 708-369 419
This information is information that Vigmed Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.00 am CET on March 22, 2017.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 600 shareholders. Remium Nordic AB is the Company’s Certified Advisor. Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor